Niki BioSolutions, Inc. (NIKI) Key Metrics
NIKI valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $6.3M
- Enterprise value
- $5.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 23.4
- Price / book
- 0.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −1.00
NIKI key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNIKI returns How much profit the business earns on the capital it uses.
NIKI financial health Debt, liquidity and how easily interest is covered.
NIKI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NIKI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NIKI cash returned to shareholders
NIKI key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Share price at fiscal year-end | $10.60 | $28.00 | $24.49 | $55.00 | $150.00 | $247.00 | $1,585.00 | $1,518.00 | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −6.2% | −18.6% | −13.9% | −49.8% | −76.6% | 24.3% | −75.5% | −46.8% | −8.4% |
| Return on invested capital (ROIC) | −6.1% | −12.1% | −35.9% | −77.0% | −106.1% | −105.3% | −61.2% | −38.0% | −36.0% |
| Return on assets (ROA) | −7.8% | −23.2% | −13.6% | −45.8% | −75.7% | 20.7% | −54.1% | −38.7% | −8.1% |
| Return on tangible assets | −7.3% | −26.5% | −13.8% | −48.7% | −119.1% | 16.3% | −82.5% | −34.0% | −8.5% |
| Free cash flow margin | — | — | — | −965.0% | −959.1% | — | — | — | — |
| Income quality (OCF / net income) | — | — | — | — | — | −2.25 | — | — | — |
| Financial health | |||||||||
| Total debt | $3.4M | $3.4M | $3.3M | $6.9M | $217,167 | $3.3M | $6.5M | $10.3M | $480,000 |
| Cash & short-term investments | $3.5M | $874,238 | $2.0M | $2.0M | $8.5M | $31.9M | $6.3M | $13.0M | $18.2M |
| Net debt | −$9,963 | $2.5M | $1.3M | $4.9M | −$8.3M | −$28.6M | $222,232 | −$2.7M | −$17.7M |
| Debt / equity | 0.15 | 0.16 | 0.13 | 0.44 | 0.01 | 0.08 | 0.40 | 0.31 | 0.02 |
| Debt / assets | 0.18 | 0.21 | 0.16 | 0.33 | 0.01 | 0.08 | 0.27 | 0.23 | 0.02 |
| Net debt / EBITDA | — | — | — | — | — | −4.40 | — | — | — |
| Current ratio | 0.78 | 0.22 | 1.18 | 0.57 | 2.90 | 8.70 | 3.00 | 2.36 | 15.24 |
| Quick ratio | 0.78 | 0.22 | 1.18 | 0.56 | 2.89 | 8.69 | 2.99 | 2.35 | 14.09 |
| Interest coverage | -19.0 | -25.8 | -87.5 | — | -205.2 | -81.7 | -4.9 | -2.3 | — |
| Working capital | −$1.0M | −$3.4M | $377,339 | −$5.4M | $8.3M | $29.8M | $5.4M | $16.5M | $19.0M |
| Invested capital | $23.2M | $23.6M | $26.1M | $20.6M | $15.3M | $13.3M | $16.6M | $30.4M | $12.5M |
| Tangible asset value | $13.8M | $11.8M | $15.2M | $7.1M | $16.6M | $37.2M | $13.5M | $31.3M | $28.8M |
| Net current asset value | −$1.3M | −$3.4M | −$2.8M | −$6.0M | $8.3M | $27.6M | −$1.1M | $16.4M | $19.0M |
| Capital allocation | |||||||||
| Dividends paid | — | — | — | — | — | $755,514 | — | — | — |
| Dividend payout ratio | — | — | — | — | — | 10.7% | — | — | — |
| Capex / revenue | — | — | 0.7% | 14.4% | 8.9% | 17.7% | 206.9% | 1,581.5% | — |
| Capex / depreciation | — | 0.00 | 0.00 | 0.12 | 0.12 | 0.12 | 0.85 | 8.89 | 51.94 |
| Stock-based compensation / revenue | — | — | 293.3% | 127.1% | 109.1% | 162.2% | 301.4% | — | — |
| R&D / revenue | — | — | 1,205.0% | 711.4% | 704.9% | 1,271.2% | 1,296.6% | 808.7% | — |
| SG&A / revenue | — | — | 1,023.5% | 614.6% | 520.6% | 845.6% | 2,014.1% | 1,755.4% | — |
| Efficiency | |||||||||
| Days sales outstanding | — | — | 616.2 | 696.5 | 461.8 | 165.9 | 504.2 | 557.0 | — |
| Days of inventory on hand | — | — | — | 9.5 | 9.4 | 13.2 | 14.9 | 899.6 | 9,523.5 |
| Days payables outstanding | — | — | — | — | — | — | — | 46.1 | — |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | 1,410.5 | — |
| Receivables turnover | — | 0.00 | 0.59 | 0.52 | 0.79 | 2.20 | 0.72 | 0.66 | 0.00 |
| Payables turnover | — | — | — | — | — | — | — | 7.92 | — |
| Inventory turnover | — | — | — | 38.30 | 38.98 | 27.69 | 24.51 | 0.41 | 0.04 |
| Asset turnover | 0.00 | 0.00 | 0.02 | 0.06 | 0.05 | 0.03 | 0.02 | 0.01 | 0.00 |
| Average receivables | — | $37,745 | $728,204 | $2.5M | $2.0M | $414,326 | $739,218 | $585,169 | $179,492 |
| Average payables | — | — | — | — | — | — | — | $40,139 | — |
| Average inventory | — | — | $13,861 | $31,748 | $37,454 | $36,659 | $32,414 | $783,760 | $1.5M |
| Intangibles / total assets | 0.0% | 0.0% | 0.7% | 3.6% | 4.0% | 2.2% | 5.5% | 3.1% | 4.7% |
Computed from NIKI's annual financial statements (latest annual report filed March 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NIKI valuation and financial ratios
Niki BioSolutions earned a return on equity of −6.2% and a return on invested capital of −6.1% in fiscal 2025. It ended the year with $3.4 million of debt and $3.5 million in cash and short-term investments, a net cash position of $0.0 million.
See the NIKI income statement, the NIKI chart for price history, or the NIKI stock overview for the latest quote and news.
NIKI key metrics FAQ
What is Niki BioSolutions's return on equity?
Niki BioSolutions's return on equity (ROE) was −6.2% in fiscal 2025: net income of -$1.4 million on average shareholders' equity of $22.1 million.
What is Niki BioSolutions's ROIC?
Niki BioSolutions's return on invested capital was −6.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Niki BioSolutions have?
Niki BioSolutions had total debt of $3.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.15 and more cash than debt.
What is Niki BioSolutions's current ratio?
Niki BioSolutions's current ratio was 0.78 at the end of fiscal 2025: current assets were 0.78 times current liabilities.